| Literature DB >> 35978630 |
Mariem Yengui1, Rahma Trabelsi1, Lamia Khannous1, Nour Elhouda Mathlouthi1, Mohd Adnan2, Arif Jamal Siddiqui2, Emira Noumi2,3, Mejdi Snoussi2,4, Radhouane Gdoura1.
Abstract
The objective of this study was to develop and evaluate newly improved, rapid, and reliable strategies based on real-time PCR to detect the most frequent beta-lactamase genes recorded in clinical Enterobacterales strains, particularly in Tunisia (blaSHV12 , blaTEM , blaCTX-M-15 , blaCTX-M-9 , blaCMY-2 , blaOXA-48 , blaNDM-1 , and blaIMP ) directly from the urine. Following the design of primers for a specific gene pool and their validation, a series of real-time PCR reactions were performed to detect these genes in 78 urine samples showing high antibiotic resistance after culture and susceptibility testing. Assays were applied to DNA extracted from cultured bacteria and collected urine. qPCR results were compared for phenotypic sensitivity. qPCR results were similar regardless of whether cultures or urine were collected, with 100% sensitivity and specificity. Out of 78 multiresistant uropathogenic, strains of Enterobacterales (44 E. coli and 34 K. pneumoniae strains) show the presence of the genes of the bla group. In all, 44% E. coli and 36 of K. pneumoniae clinical strains harbored the bla group genes with 36.4%, 52.3%, 70.5%, 68.2%, 18.2%, and 4.5% of E. coli having blaSHV-12 , blaTEM , blaCTX-M 15 , blaCTX-M-9 , blaCMY-2 , and blaOXA-48 group genes, respectively, whereas 52.9%, 67.6%, 76.5%, 35.5%, 61.8, 14.7, and 1.28% of K. pneumoniae had blaSHV-12 , blaTEM , blaCTX-M 15 , blaCTX-M-9 , blaCMY-2 , blaOXA-48 , and blaNDM-1 group genes, respectively. The time required to have a result was 3 hours by real-time PCR and 2 to 3 days by the conventional method. Resistance genes of Gram-negative bacteria in urine, as well as cultured bacteria, were rapidly detected using qPCR techniques. These techniques will be used as rapid and cost-effective methods in the laboratory. Therefore, this test could be a good candidate to create real-time PCR kits for the detection of resistance genes directly from urine in clinical or epidemiological settings.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35978630 PMCID: PMC9377892 DOI: 10.1155/2022/8612933
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
List of primers used for qPCR amplification of ESBLs and carbapenemase genes.
| Genes | Primer sequence (5′→3′) | T°m | Product size (bp) | GenBank |
|---|---|---|---|---|
|
| FW: AGCCGCTTGAGCAAATTAAA | 59.99 | 77 | LC229232.1 |
| RV: GCTGGCCAGATCCATTTCTA | 60.18 | |||
|
| ||||
|
| FW: GATAAATCTGGAGCCGGTGA | 60.04 | 78 | MG860488.1 |
| RV: GATACGGGAGGGCTTACCAT | 60.17 | |||
|
| ||||
|
| FW: CACCAATGATATTGCGGTGA | 60.34 | 77 | MG288677.1 |
| RV: GTTGCGGCTGGGTAAAATAG | 59.61 | |||
|
| ||||
|
| FW: TACTTCACCCAGCCTCAACC | 60.11 | 78 | CP028990.1 |
| RV: ACCGTCGGTGACGATTTTAG | 59.99 | |||
|
| ||||
|
| FW: CCAGAACTGACAGGCAAACA | 59.87 | 65 | LC229227 |
| RV: CCTGCCGTATAGGTGGCTAA | 60.11 | |||
|
| ||||
|
| FW: GTAGTCAGCGCATCGTGAAA | 60.02 | 73 | MN654469.1 |
| RV: CCCGTTTTAGCCCGAATAAT | 60.12 | |||
|
| ||||
|
| FW: GCCAAAGTCCGCCAAATTAT | 60.17 | 92 | MK088089.1 |
| RV: TCAAGAGTGATGCGTCTCCA | 65.56 | |||
|
| ||||
|
| FW: ATGGAGACTGGCGACCAAC | 61.10 | 87 | LC413788.2 |
| RV: GGCATGTCGAGATAGGAAGG | 59.65 | |||
Specificity and sensitivity of the qPCR system for bla group gene detection.
| Resistance gene target | Clinical urines ( | Strains ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| True (+) = A | False (-) = B | False (+) = C | True (-) = D | Sensitivity; specificity, % | True (+) = A | False (-) = B | False (+) = C | True (-) = D | Sensitivity; specificity, % | |
|
| 34 | 0 | 0 | 44 | 100; 100 | 34 | 0 | 0 | 44 | 100; 100 |
|
| 46 | 0 | 0 | 32 | 100; 100 | 46 | 0 | 0 | 32 | 100; 100 |
|
| 56 | 0 | 0 | 22 | 100; 100 | 56 | 0 | 0 | 22 | 100; 100 |
|
| 42 | 0 | 0 | 36 | 100; 100 | 42 | 0 | 0 | 36 | 100; 100 |
|
| 29 | 0 | 0 | 49 | 100; 100 | 29 | 0 | 0 | 49 | 100; 100 |
|
| 7 | 0 | 0 | 71 | 100; 100 | 7 | 0 | 0 | 71 | 100; 100 |
|
| 0 | 0 | 0 | 78 | 100; 100 | 0 | 0 | 0 | 78 | 100; 100 |
|
| 1 | 0 | 0 | 77 | 100; 100 | 1 | 0 | 0 | 77 | 100; 100 |
The most frequent gene combinations in E. coli and K. pneumoniae strains.
| Genotype |
|
|
|---|---|---|
| Number of strains ( | Number of strains ( | |
|
| 10 | 6 |
|
| 10 | 7 |
|
| 5 | 5 |
|
| 2 | 1 |
Figure 1Distribution of the 7 resistance genes in the 44 E. coli and 34 K. pneumoniae clinical strains.
Antibiotic susceptibility profile of multidrug E. coli and K. pneumoniae.
| Antibiotics |
|
| ||
|---|---|---|---|---|
| Resistant | Sensitive | Resistant | Sensitive | |
| AMX | 100% (44) | 0 | 100%(34) | 0 |
| AMC | 97.7% (43) [87.99%-99.92%] | 2.3% (1) | 100%(34) | 0 |
| TIC | 100% (44) | 0 | 100%(34) | 0 |
| CF | 100% (44) | 0 | 100%(34) | 0 |
| FOX | 9.1% (4) [2.53%-21.66%] | 90.9% (40) [78.33%-97.46%] | 41.2% (14) [24.64%-59.30%] | 58.8% (20) [40.69%-75.35%] |
| CFM | 97.7% (43) [87.99%-99.92%] | 2.3% (1) | 97.1% (33)[84.67%-99.92%] | 2.9% (1) |
| CAZ | 97.7% (43) [87.99%-99.92%] | 2.3% (1) | 94.1% (32) [80.32%-99.27%] | 5.9% (2) [0.72%-1.96%] |
| CTX | 97.7% (43) [87.99%-99.92%] | 2.3% (1) | 97.1% (33) [84.67%-99.92%] | 2.9% (1) |
| IMP | 2.3% (1) | 97.7%(43) [87.99%-99.92%] | 29.4% (10) [15.09%-47.47%] | 70.6% (24) [52.52%-84.90%] |
| AN | 25% (11) [13.19%-40.33%] | 75% (33) [59.66%-86.80%] | 17.6% (6) [6.76%-34.53%] | 82.4% (28) [65.46%-93.23%] |
| GM | 45.5% (20) [30.39%-61.15%] | 54.5% (24)[38.84%-69.60%] | 61.8% (21) [43.56%-77.83%] | 38.2% (13) [22.16%-56.43%] |
| NET | 59.1% (26) [43.24%-73.66%] | 40.9% (18)[26.33%-56.75%] | 52.9% (18) [35.12%-70.22%] | 47.1% (16) [29.77%-64.87%] |
| NN | 63.6% (28) [47.77%-77.59%] | 36.4% (16)[22.40%-52.2%] | 61.8% (21) [43.56%-77.83%] | 38.2% (13) [22.16%-56.43%] |
| NA | 88.6% (39) [75.44%-96.20%] | 11.4% (5)[11.36%-37.94%] | 85.3% (29) [68.94%-95.04%] | 14.7% (5) [4.95%-31.05%] |
| OFX | 95.5% (42) [84.52%-99.44%] | 4.5% (2)[0.5%-1.54%] | 85.3% (29) [68.94%-95.04%] | 14.7% (5) [4.95%-31.05%] |
| CIP | 93.2% (41) [81.34%-98.57%] | 6.8% (3)[1.42%-18.65%] | 82.4% (28) [65.46%-93.23%] | 17.6% (6) [6.76%-34.53%] |
| FFL | 9.1% (4) [2.53%-21.66%] | 90.9% (40)[78.33%-97.46%] | 50% (17) [32.42%-67.57%] | 50% (17) [32.42%-67.57%] |
| SXT | 68.2% (30) [52.42%-81.39%] | 31.8% (14)[18.60%-47.57%] | 67.6% (23)[49.47%-82.61%] | 32.4% (11) [17.38%-50.52%] |
| CL | 0 | 100% (44) | 0 | 100%(34) |
AMX: amoxicillin; AMC: amoxicillin + clavulanic acid; TIC; ticarcillin; CF: cephalexin; CFM: cefixime; FOX: cefoxitin; CTX: cefotaxime; CAZ: ceftazidime; IMP: imipenem; NA: nalidixic acid; OFX: ofloxacin; CIP: ciprofloxacin; AN: amikacin, GM: gentamycin; NET: netilmicin; NN: tobramycin; FFL: fosfomycine; SXT: trimethoprim + sulfamide; CL: colistin.
Correlation between bla genes and antibiotic resistance in the 78 clinical strains (by the χ2 test).
| Antibiotics |
|
|
|
|
|
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| + | - |
| + | - |
| + | - |
| + | - |
| + | - |
| + | - |
| |
| Resistance to ≥4 | 32.60% (15/46) | 6.25% | 0.006 | 23.52% | 20.45% | 0.744 | 33.33% | 8.33% | 0.008 | 17.85% | 31.81% | 0.179 | - | - | — | 66.66% | 18.05% | 0.006 |
Relationship between bla genes and antibiotic resistance in the 78 clinical strains (by multiple logistic regression analysis).
| Antibiotics | Resistance rate % (positive/total) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||||||||||||
|
|
| OR |
|
| OR |
|
| OR |
|
| OR |
|
| OR |
|
| OR | |
| Resistance to ≥4 | 5.921 | 0.015 | 9.372 | — | — | — | 3.764 | 0.05 | 4.448 | — | — | — | — | — | — | 5.049 | 0.025 | 13.100 |
| FOX | — | — | — | — | — | — | — | — | — | — | — | — | 9.835 | 0.002 | 11.136 | — | — | — |
Correlation between bla genes and antibiotic resistance in the 78 clinical strains (by Spearman's rank correlation analysis).
| Antibiotics | Resistance rate % (positive/total) | |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
| Resistance to ≥4 beta-lactam antibiotics | 0.002 | 0.404 | 0.024 | 0.264 | — | 0.002 |
| FOX | — | — | — | — | 0.022 | 0.008 |